Cancer-focused cell therapy company OverT Bio emerged from stealth with USD 16 million in seed financing co-led by ARTIS Ventures and Wing VC. Other investors included Fusion Fund, OMX Ventures, and Alexandria Venture Investments, among others.
The proceeds will be channeled toward enhancing discovery platforms, focusing specifically on developing novel cell therapies targeting advanced solid tumors.
OverT Bio specializes in the development of cellular therapies for the treatment of solid tumors by leveraging pooled functional screening and synthetic genomics platforms named OverTarget and OverTune. These platforms facilitate the creation of next-generation engineered immune cells, aiming to advance the field of immunotherapy for cancer treatment. Its approach entails researching the whole human genome to enhance the longevity and ability of cell therapies in eradicating cancers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.